Product Description
GL-1 Molecule (Prescription Only)
Available in 5mg, 10mg, and 20mg Total Dose Vials
GL-1 Therapy for Weight Loss, Appetite Control & Metabolic Reset
Formulations (All at 5mg / 2mL Concentration)
-
GL-1 Core 5: 2mL vial containing 5mg total GL-1
-
GL-1 Core 10: 4mL vial containing 10mg total GL-1
-
GL-1 Core 20: 8mL vial containing 20mg total GL-1
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-1 Therapy?
GL-1 is a prescription incretin-based therapy that activates the body’s glucagon-like peptide-1 (GLP-1) receptor, a key regulator of appetite, satiety, glucose control, and metabolic signaling.
By mimicking the body’s natural satiety hormone, GL-1 therapy helps:
-
Reduce hunger and caloric intake
-
Improve insulin sensitivity and glycemic control
-
Promote sustained fat loss
-
Lower systemic and metabolic inflammation
GL-1–based therapy has become the foundation of modern medical weight-loss protocols and is widely used under clinical supervision for metabolic health optimization.
All GL-1 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Appetite Suppression & Satiety Signaling
GL-1 receptor activation slows gastric emptying and acts on hypothalamic appetite centers to reduce hunger and increase fullness.
STEP-1 Trial (Wilding et al., NEJM, 2021)
– Demonstrated ~15% total body-weight reduction over 68 weeks with weekly GL-1–based therapy.
🩸 Blood Sugar & Insulin Sensitivity Improvement
GL-1 signaling enhances glucose-dependent insulin release while suppressing glucagon, improving metabolic efficiency and glycemic stability.
SUSTAIN-6 Trial (Marso et al., 2016)
– Showed significant HbA1c reduction and reduced cardiovascular risk with GL-1 receptor agonist therapy.
🧠 Craving Reduction & “Food Noise” Control
GL-1 activity modulates reward-center signaling, decreasing dopamine-driven food cravings and compulsive eating behaviors.
van Bloemendaal et al., 2014
– Neuroimaging studies showed reduced food motivation and reward response with GL-1 activation.
💪 Preservation of Lean Mass During Fat Loss
Weight reduction achieved with GL-1 therapy is predominantly from adipose tissue rather than muscle.
Heymsfield et al., 2023 (Obesity)
– Lean mass preserved in >85% of patients during GL-1–mediated weight loss.
⚕️ Clinical Access & Consultation Required
GL-1 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth consultation or established prescription required
✔ Labs may be requested (glucose, HbA1c, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing clinical guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-1 Variants)
Each vial provides 5mg GL-1 per 2mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-1 | Estimated Duration |
|---|---|---|---|
| GL-1 Core 5 | 2 mL | 5 mg | ~2–4 weeks |
| GL-1 Core 10 | 4 mL | 10 mg | ~4–8 weeks |
| GL-1 Core 20 | 8 mL | 20 mg | ~8–12+ weeks |
Starting Dose: 20 units weekly (0.5 mg)
Titration Strategy:
• Increase by 10 units (0.25 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 40–60 units weekly (1–1.5 mg), based on patient goals and response
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, BPC-157, GHK-Cu, or Tesamorelin for metabolic, inflammatory, and body-composition support
📦 What’s Included With Every Order
✔ 1 × GL-1 Molecule vial (Core 5, 10, or 20)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Foundational Weight Loss. Clinical Oversight. Sustainable Results.
GL-1 Core Therapy provides a proven, provider-guided approach to metabolic health and weight loss, structured for safety, sustainability, and long-term success.
Start with GL-1 Core 5.
Scale with GL-1 Core 10.
Maintain progress with GL-1 Core 20.
All options include medical consultation and individualized dosing guidance
Directions For Use
GL-1 Molecule (Prescription Only)
Available in 5mg, 10mg, and 20mg Total Dose Vials
GL-1 Therapy for Weight Loss, Appetite Control & Metabolic Reset
Formulations (All at 5mg / 2mL Concentration)
-
GL-1 Core 5: 2mL vial containing 5mg total GL-1
-
GL-1 Core 10: 4mL vial containing 10mg total GL-1
-
GL-1 Core 20: 8mL vial containing 20mg total GL-1
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-1 Therapy?
GL-1 is a prescription incretin-based therapy that activates the body’s glucagon-like peptide-1 (GLP-1) receptor, a key regulator of appetite, satiety, glucose control, and metabolic signaling.
By mimicking the body’s natural satiety hormone, GL-1 therapy helps:
-
Reduce hunger and caloric intake
-
Improve insulin sensitivity and glycemic control
-
Promote sustained fat loss
-
Lower systemic and metabolic inflammation
GL-1–based therapy has become the foundation of modern medical weight-loss protocols and is widely used under clinical supervision for metabolic health optimization.
All GL-1 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Appetite Suppression & Satiety Signaling
GL-1 receptor activation slows gastric emptying and acts on hypothalamic appetite centers to reduce hunger and increase fullness.
STEP-1 Trial (Wilding et al., NEJM, 2021)
– Demonstrated ~15% total body-weight reduction over 68 weeks with weekly GL-1–based therapy.
🩸 Blood Sugar & Insulin Sensitivity Improvement
GL-1 signaling enhances glucose-dependent insulin release while suppressing glucagon, improving metabolic efficiency and glycemic stability.
SUSTAIN-6 Trial (Marso et al., 2016)
– Showed significant HbA1c reduction and reduced cardiovascular risk with GL-1 receptor agonist therapy.
🧠 Craving Reduction & “Food Noise” Control
GL-1 activity modulates reward-center signaling, decreasing dopamine-driven food cravings and compulsive eating behaviors.
van Bloemendaal et al., 2014
– Neuroimaging studies showed reduced food motivation and reward response with GL-1 activation.
💪 Preservation of Lean Mass During Fat Loss
Weight reduction achieved with GL-1 therapy is predominantly from adipose tissue rather than muscle.
Heymsfield et al., 2023 (Obesity)
– Lean mass preserved in >85% of patients during GL-1–mediated weight loss.
⚕️ Clinical Access & Consultation Required
GL-1 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth consultation or established prescription required
✔ Labs may be requested (glucose, HbA1c, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing clinical guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-1 Variants)
Each vial provides 5mg GL-1 per 2mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-1 | Estimated Duration |
|---|---|---|---|
| GL-1 Core 5 | 2 mL | 5 mg | ~2–4 weeks |
| GL-1 Core 10 | 4 mL | 10 mg | ~4–8 weeks |
| GL-1 Core 20 | 8 mL | 20 mg | ~8–12+ weeks |
Starting Dose: 20 units weekly (0.5 mg)
Titration Strategy:
• Increase by 10 units (0.25 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 40–60 units weekly (1–1.5 mg), based on patient goals and response
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, BPC-157, GHK-Cu, or Tesamorelin for metabolic, inflammatory, and body-composition support
📦 What’s Included With Every Order
✔ 1 × GL-1 Molecule vial (Core 5, 10, or 20)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Foundational Weight Loss. Clinical Oversight. Sustainable Results.
GL-1 Core Therapy provides a proven, provider-guided approach to metabolic health and weight loss, structured for safety, sustainability, and long-term success.
Start with GL-1 Core 5.
Scale with GL-1 Core 10.
Maintain progress with GL-1 Core 20.
All options include medical consultation and individualized dosing guidance
Ingredients
GL-1 Molecule (Prescription Only)
Available in 5mg, 10mg, and 20mg Total Dose Vials
GL-1 Therapy for Weight Loss, Appetite Control & Metabolic Reset
Formulations (All at 5mg / 2mL Concentration)
-
GL-1 Core 5: 2mL vial containing 5mg total GL-1
-
GL-1 Core 10: 4mL vial containing 10mg total GL-1
-
GL-1 Core 20: 8mL vial containing 20mg total GL-1
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-1 Therapy?
GL-1 is a prescription incretin-based therapy that activates the body’s glucagon-like peptide-1 (GLP-1) receptor, a key regulator of appetite, satiety, glucose control, and metabolic signaling.
By mimicking the body’s natural satiety hormone, GL-1 therapy helps:
-
Reduce hunger and caloric intake
-
Improve insulin sensitivity and glycemic control
-
Promote sustained fat loss
-
Lower systemic and metabolic inflammation
GL-1–based therapy has become the foundation of modern medical weight-loss protocols and is widely used under clinical supervision for metabolic health optimization.
All GL-1 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Appetite Suppression & Satiety Signaling
GL-1 receptor activation slows gastric emptying and acts on hypothalamic appetite centers to reduce hunger and increase fullness.
STEP-1 Trial (Wilding et al., NEJM, 2021)
– Demonstrated ~15% total body-weight reduction over 68 weeks with weekly GL-1–based therapy.
🩸 Blood Sugar & Insulin Sensitivity Improvement
GL-1 signaling enhances glucose-dependent insulin release while suppressing glucagon, improving metabolic efficiency and glycemic stability.
SUSTAIN-6 Trial (Marso et al., 2016)
– Showed significant HbA1c reduction and reduced cardiovascular risk with GL-1 receptor agonist therapy.
🧠 Craving Reduction & “Food Noise” Control
GL-1 activity modulates reward-center signaling, decreasing dopamine-driven food cravings and compulsive eating behaviors.
van Bloemendaal et al., 2014
– Neuroimaging studies showed reduced food motivation and reward response with GL-1 activation.
💪 Preservation of Lean Mass During Fat Loss
Weight reduction achieved with GL-1 therapy is predominantly from adipose tissue rather than muscle.
Heymsfield et al., 2023 (Obesity)
– Lean mass preserved in >85% of patients during GL-1–mediated weight loss.
⚕️ Clinical Access & Consultation Required
GL-1 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth consultation or established prescription required
✔ Labs may be requested (glucose, HbA1c, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing clinical guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-1 Variants)
Each vial provides 5mg GL-1 per 2mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-1 | Estimated Duration |
|---|---|---|---|
| GL-1 Core 5 | 2 mL | 5 mg | ~2–4 weeks |
| GL-1 Core 10 | 4 mL | 10 mg | ~4–8 weeks |
| GL-1 Core 20 | 8 mL | 20 mg | ~8–12+ weeks |
Starting Dose: 20 units weekly (0.5 mg)
Titration Strategy:
• Increase by 10 units (0.25 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 40–60 units weekly (1–1.5 mg), based on patient goals and response
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, BPC-157, GHK-Cu, or Tesamorelin for metabolic, inflammatory, and body-composition support
📦 What’s Included With Every Order
✔ 1 × GL-1 Molecule vial (Core 5, 10, or 20)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Foundational Weight Loss. Clinical Oversight. Sustainable Results.
GL-1 Core Therapy provides a proven, provider-guided approach to metabolic health and weight loss, structured for safety, sustainability, and long-term success.
Start with GL-1 Core 5.
Scale with GL-1 Core 10.
Maintain progress with GL-1 Core 20.
All options include medical consultation and individualized dosing guidance
Disclaimer
GL-1 Molecule (Prescription Only)
Available in 5mg, 10mg, and 20mg Total Dose Vials
GL-1 Therapy for Weight Loss, Appetite Control & Metabolic Reset
Formulations (All at 5mg / 2mL Concentration)
-
GL-1 Core 5: 2mL vial containing 5mg total GL-1
-
GL-1 Core 10: 4mL vial containing 10mg total GL-1
-
GL-1 Core 20: 8mL vial containing 20mg total GL-1
Classification: Prescription Only – Requires Provider Consultation & Approval
What Is GL-1 Therapy?
GL-1 is a prescription incretin-based therapy that activates the body’s glucagon-like peptide-1 (GLP-1) receptor, a key regulator of appetite, satiety, glucose control, and metabolic signaling.
By mimicking the body’s natural satiety hormone, GL-1 therapy helps:
-
Reduce hunger and caloric intake
-
Improve insulin sensitivity and glycemic control
-
Promote sustained fat loss
-
Lower systemic and metabolic inflammation
GL-1–based therapy has become the foundation of modern medical weight-loss protocols and is widely used under clinical supervision for metabolic health optimization.
All GL-1 products provided by PROpeptides require a clinical consultation and prescription from a licensed providerprior to dispensing.
🔬 Key Research-Based Mechanisms
🔥 Appetite Suppression & Satiety Signaling
GL-1 receptor activation slows gastric emptying and acts on hypothalamic appetite centers to reduce hunger and increase fullness.
STEP-1 Trial (Wilding et al., NEJM, 2021)
– Demonstrated ~15% total body-weight reduction over 68 weeks with weekly GL-1–based therapy.
🩸 Blood Sugar & Insulin Sensitivity Improvement
GL-1 signaling enhances glucose-dependent insulin release while suppressing glucagon, improving metabolic efficiency and glycemic stability.
SUSTAIN-6 Trial (Marso et al., 2016)
– Showed significant HbA1c reduction and reduced cardiovascular risk with GL-1 receptor agonist therapy.
🧠 Craving Reduction & “Food Noise” Control
GL-1 activity modulates reward-center signaling, decreasing dopamine-driven food cravings and compulsive eating behaviors.
van Bloemendaal et al., 2014
– Neuroimaging studies showed reduced food motivation and reward response with GL-1 activation.
💪 Preservation of Lean Mass During Fat Loss
Weight reduction achieved with GL-1 therapy is predominantly from adipose tissue rather than muscle.
Heymsfield et al., 2023 (Obesity)
– Lean mass preserved in >85% of patients during GL-1–mediated weight loss.
⚕️ Clinical Access & Consultation Required
GL-1 therapy is prescription-only and will not be shipped without provider approval.
✔ Telehealth consultation or established prescription required
✔ Labs may be requested (glucose, HbA1c, IGF-1, lipid panel)
✔ Individualized prescription and titration plan
✔ Ongoing clinical guidance and follow-up support
💉 Dosing Protocol (Applies to All GL-1 Variants)
Each vial provides 5mg GL-1 per 2mL of solution. Vial size determines total available dose.
| Variant | Volume | Total GL-1 | Estimated Duration |
|---|---|---|---|
| GL-1 Core 5 | 2 mL | 5 mg | ~2–4 weeks |
| GL-1 Core 10 | 4 mL | 10 mg | ~4–8 weeks |
| GL-1 Core 20 | 8 mL | 20 mg | ~8–12+ weeks |
Starting Dose: 20 units weekly (0.5 mg)
Titration Strategy:
• Increase by 10 units (0.25 mg) only after two consecutive weeks with no weight loss and no side effects
• Reduce dose by 10 units if side effects occur, then resume titration as tolerated
Typical Max Dose: 40–60 units weekly (1–1.5 mg), based on patient goals and response
Route: Subcutaneous injection (abdomen or flank)
Duration: Weekly dosing for 3–6+ months
Stack Compatibility: Commonly paired with KPV, BPC-157, GHK-Cu, or Tesamorelin for metabolic, inflammatory, and body-composition support
📦 What’s Included With Every Order
✔ 1 × GL-1 Molecule vial (Core 5, 10, or 20)
✔ Pre-measured bacteriostatic water
✔ Insulin syringes & alcohol swabs
✔ Sharps container bag
✔ Printed dosing & titration guide
✔ Telehealth consultation & provider oversight
Need Assistance?
Email: Admin@Propeptides.com
Call/Text: 480-400-6225
🛡️ Foundational Weight Loss. Clinical Oversight. Sustainable Results.
GL-1 Core Therapy provides a proven, provider-guided approach to metabolic health and weight loss, structured for safety, sustainability, and long-term success.
Start with GL-1 Core 5.
Scale with GL-1 Core 10.
Maintain progress with GL-1 Core 20.
All options include medical consultation and individualized dosing guidance
